40 results about "Apoptosis induction" patented technology

The invention relates to the technical field of medicines, and discloses an application of combination of bufalin and heme in preparation of a cancer treatment medicine. According to the invention, by means of an active metabonomics means, a key active metabolite-heme is locked through exogenous library screening and endogenous analysis, and the drug effect of bufalin is regulated by means of the active metabolite. Through verification, it is found that heme can cooperate with the synergistic drug effect in various cancer cell lines, and a new technical normal form based on an active metabolome for improving the drug effect of bufalin is provided. The pharmaceutical composition can improve the apoptosis induction ability of bufalin to different cancer cells, and provides powerful guiding significance for developing a novel treatment scheme in clinical medicine.

The invention belongs to the technical field of medicines, and particularly relates to application of dioscin combined with chidamide in diffuse large B-cell lymphoma. Specifically, research finds that the dioscin can significantly inhibit DLBCL cell proliferation and induce cell cycle arrest and apoptosis by up-regulating PINK1 / Parkin mediated mitochondrial autophagy and enhancing H3K27 acetylation mediated epigenetic regulation. When the chidamide and the dioscin are combined for use, a synergistic effect can be generated, and by further increasing the H3K27ac level, the cell apoptosis induction effect is enhanced, and the in-vivo and in-vitro anti-tumor activity on DLBCL is remarkably improved. The invention provides a novel and efficient DLBCL combined treatment scheme, and provides a new pharmaceutical composition and theoretical support for clinical diagnosis and treatment of DLBCL, so that the application has good practical application value.

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The present application relates to a method for preparing a dendritic cell for producing a T cell adapter, comprising the steps of: preparing a nucleic acid construct encoding a multispecific T cell adapter comprising a first antigen binding domain and a second binding domain for specifically binding to CD3 on the surface of a T cell to activate the T cell, the second binding domain is an apoptosis inducing ligand TRAIL; and transferring the nucleic acid construct as an exogenous nucleic acid into the DC cell to obtain the dendritic cell for generating the T cell adapter. The dendritic cell for generating the T cell adapter can assist a human immune system in better and more targeted killing of tumor cells.

The invention discloses skin mucosa maintenance liquid capable of killing fungi and HPV (human papillomavirus) as well as a preparation method and application of the skin mucosa maintenance liquid, and belongs to the technical field of sterilization and virus removal. The skin mucosa maintenance liquid is prepared from octanol ether, benzalkonium bromide, phenoxyethanol, yermate, parachlorometaxylenol, taetinic acid, chitosan, keratinase, fluconazole, glycerol, borneol, menthol, absolute ethyl alcohol and tween-40. Wherein the skin mucosa maintenance liquid has an effect of regulating apoptosis induction on abnormal cells and an effect on vaginal flora, and has an obvious inhibition effect on cervicitis and colpitis mycotica, namely an anti-inflammatory effect; meanwhile, apoptosis of cells containing HPV16 and HPV18 genes can be induced, shedding of abnormal cells is promoted, diseased cells are killed, and vaginal tissues with pathological changes are removed.

The invention discloses a thiosemicarbazone compound containing a naphthyl structure as well as a preparation method and application of the thiosemicarbazone compound. The thiosemicarbazone compound has biological activity on human breast cancer cells. The anti-tumor activity of the compound is verified through in-vitro experiments, including an inhibition effect experiment of the compound on proliferation of human breast cancer cells, an influence experiment on oxidative stress level of the breast cancer cells, an influence experiment on mitochondrial membrane potential of the breast cancer cells and an experiment for inducing apoptosis of the breast cancer cells. The thiosemicarbazone compound containing the naphthyl structure has remarkable anti-tumor activity, can effectively inhibit proliferation of human breast cancer cells, can remarkably improve the oxidative stress level of the breast cancer cells in a concentration-dependent mode, and has a close correlation between the regulation effect on the mitochondrial membrane potential of the breast cancer cells and the treatment concentration; the compound can effectively induce apoptosis of breast cancer cells, has excellent anti-breast cancer activity, and provides important candidate compounds and theoretical basis for research and development of novel anti-tumor drugs.

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

The invention discloses a tumor cell proliferation inhibition physiotherapy device and method based on a specific-intensity micro magnetic field, and belongs to the field of medical instruments.The tumor cell proliferation inhibition physiotherapy device comprises a main board, a rear board is fixed to the rear portion of the upper surface of the main board, a front board is rotatably connected to the front end of the main board, and the left side and the right side of the main board are each provided with two rotating grooves; the universal wheels are arranged at the bottom and matched with a handle of the rear plate, so that flexible pushing can be achieved, the moving direction can be controlled, and transferring is convenient and fast; a folding structure is provided, the support can be driven to retract by turning over the side plates and the front plate, the size of the device is reduced, meanwhile, physiotherapy equipment can be wrapped and protected, losses in the transportation and storage process are reduced, and space is saved; the physiotherapy equipment generates a 1-100mT specific intensity micro magnetic field through current, and cooperates with a warm effect to inhibit tumor cell proliferation from multiple aspects of cell cycle interference, energy metabolism destruction and apoptosis induction, so that the physiotherapy effect is ensured.

The invention discloses an application of brucein D and Vinetoram in preparation of a medicine for treating acute or drug-resistant myelogenous leukemia. Through a large number of experimental screening, the brucein D and the Venotocork are combined for medication, and the test result shows that the brucein D and the Venotocork act on different targets and different signal channels of AML cells to generate a remarkable synergistic anti-tumor effect, and after the brucein D and the Venotocork are combined, the proliferation inhibition and apoptosis induction effects on the AML cells can be directly enhanced, and the anti-tumor effect of the Venotocork D and the AML cells can be improved. The compound can also reverse the drug resistance possibly occurring when the Vinetoram is singly used, and also has a remarkable killing effect on chemotherapy drug-resistant AML cells at the same time. The composition provided by the invention can reduce the dosage of antitumor drugs, reduce drug resistance, reduce adverse reactions and improve the life quality of patients, and has important application prospects.

The invention relates to stem cell-derived engineered nano-vesicles (e-NVs) for promoting hair growth, the engineered nano-vesicles are prepared from stem cells through engineering induction, apoptosis induction and programmed serial extrusion processes in sequence, and an inducer used for engineering induction is 3, 3 '-diindolylmethane. The particle size of the engineered nano vesicle is mainly distributed in a range of 50-300 nm, the polydispersity coefficient is 0.05-0.20, and the expression proportion of phosphatidylserine is 40%-50%. The rice vesicles can effectively improve the hair follicle microenvironment, adjust the hair growth cycle, promote proliferation and differentiation of hair follicle stem cells and remarkably increase the hair regeneration rate of androgenetic alopecia model mice, and a safe, convenient and efficient clinical strategy is provided for hair regeneration treatment.

This invention relates to the field of biomedical technology, and more particularly to a method for preparing mesenchymal stem cell apoptotic vesicles. The method primarily employs serum-free culture medium for 3D microsphere culture of stem cells, followed by induction of apoptosis into apoptotic vesicles using an apoptosis induction system, resulting in highly efficient apoptotic vesicles. This method significantly enhances the bidirectional immunomodulatory effect of stem cell-derived apoptotic vesicles, greatly expanding the application range and therapeutic efficacy of these vesicles. The serum-free culture medium avoids the safety risks and batch-to-batch variations associated with traditional culture media, and significantly improves the proliferation capacity, passage stability, and immunomodulatory effect of stem cells, enabling stable and efficient acquisition of apoptotic vesicles.

The invention relates to the technical field of biological medicines, and particularly discloses a cancer suppression small interfering RNA (Ribonucleic Acid) capable of simultaneously targeting cancer genes PTTG1 and STMN1 and application of the cancer suppression small interfering RNA, and the technical key points are as follows: the positive-sense strand sequence of the small interfering RNA is GGGAGAUCUCAAGUUUCAATT, and the antisense strand sequence of the small interfering RNA is UUGAAACUUGAGAUCUCCCTT. The small interfering RNA provided by the invention can specifically silence the expression of PTTG1 and STMN1 at the same time. Compared with siRNA (such as siRNA for ASCC3 or TRAPPC4) targeting a single gene in the prior art, the siRNA provided by the invention has the advantages that synergistic inhibition on tumor proliferation and metastasis pathways is realized through double-targeting design, and the inhibition effect on tumor cell growth is more remarkable; compared with a method of physically mixing two single siRNAs, the method provided by the invention has higher cell apoptosis induction efficiency and better in-vivo tumor inhibition effect; the small interfering RNA is effective in various liver cancer cells, has a lasting effect in an animal model, and provides a core molecular entity for developing novel antitumor drugs.

The application belongs to the technical field of medicine, and particularly relates to paclitaxel / molybdenum boride nanomaterial and a preparation method and application thereof. 4 / 3 B 2‑x Nanosheet material, the material improves the stability of Mo 4 / 3 B 2‑x Nanosheet by introducing soybean phospholipid, has the characteristics of simple preparation, high drug loading rate and high photo-thermal conversion efficiency. After the nanomaterial loads paclitaxel, as a dual-functional nanodrug for chemotherapy and photo-thermal therapy, when used for lung adenocarcinoma cells, the apoptosis of cancer cells is induced, and the induction effect is better than that of Taxol and Mo 4 / 3 B 2‑x +IR alone. When the nanodrug is applied to a mouse lung cancer model, the growth of the tumor is significantly inhibited, and the inhibition effect is better than that of Taxol and Mo 4 / 3 B 2‑x +IR alone. The results show that the Taxol / Mo 4 / 3 B 2‑x Nanosheet has a synergistic effect when used for lung cancer treatment.

The disclosure provides synthetic cytotoxic cells, comprising a hydrogel microsphere and a TNF-related apoptosis-inducing ligand (TRAIL), or active fragment thereof. In aspects, the TRAIL or active fragment thereof is attached to the surface of the hydrogel microsphere. The disclosure further provides methods of preparing the synthetic cytotoxic cells and methods of use thereof in the treatment of cancer.

The application discloses application of convallatoxin in preparation of a medicine for resisting prostate cancer and belongs to the technical field of biological medicines. The application finds that the convallatoxin has the efficacy of resisting prostate cancer, and the increase of UPP1 expression can enhance the inhibiting effect or the apoptosis induction effect of the convallatoxin on prostate cancer cells. Compared with the group of using the convallatoxin alone, after the 22Rv1 cells overexpressing UPP1 are treated by the convallatoxin, the apoptosis rate of the cells is increased by about 4 times, which indicates that the increase of UPP1 expression can enhance the effect of the convallatoxin on inducing the apoptosis of the prostate cancer cells.

The application discloses a preparation method of a bone formation inducing biological additive based on red blood cell-derived apoptotic vesicles and application thereof, and the preparation method comprises the following steps: a, red blood cell apoptosis induction treatment; b, collection and purification of red blood cell-derived apoptotic vesicles RBC-ApoEVs through series differential ultracentrifugation; c, characterization and quality control of the apoptotic vesicles; d, acquisition, culture and basic identification of SHED; and e, determination of 0.5 mu g / mL as the optimal bone formation inducing synergistic concentration of the red blood cell-derived apoptotic vesicles RBC-ApoEVs. The bone formation inducing biological additive prepared by the preparation method can be used as a safe and efficient bone formation inducing synergistic agent, and can solve the problem that "proliferation promotion" and "differentiation promotion" are difficult to be coordinated, and can also avoid the dependence on exogenous growth factors and related risks. The bone formation inducing biological additive can be applied to in-vitro induction of SHED bone differentiation, bone regeneration cell suspension and bone tissue engineering compound.

The purpose of the present invention is to provide a novel means that targets M1 microglia and is useful for the treatment of central nervous system diseases and the like. Provided is an M1 microglia-targeting fusion peptide in which an M1 microglia-targeting peptide and an apoptosis-inducing peptide are directly or indirectly linked to each other, wherein the M1 microglia-targeting peptide is a peptide mentioned in (1) or (2): (1) a peptide which has a structure such that at least one cysteine residue is directly linked to each of both ends of the amino acid sequence represented by HHSSSAR (SEQ ID NO: 1) or an amino acid sequence formed by linking a plurality of the sequences; and (2) a peptide which comprises an amino acid sequence having a structure such that one amino acid residue is or a plurality of amino acid residues are deleted, substituted or added in the amino acid sequence for the peptide (1) and which targets M1 microglia.

The present application provides multispecific antigen-binding proteins (e.g., antibodies) that specifically bind TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin 17 (CDH17). The application also provides conjugates comprising the multispecific antigen-binding proteins, polynucleotides and recombinant vectors encoding the multispecific antigen-binding proteins, as well as host cells and methods for preparing the multispecific antigen-binding proteins. The application further provides pharmaceutical compositions comprising the multispecific antigen-binding proteins andmethods for treating a disease or disorder using the multispecific antigen-binding proteins.

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

The invention relates to a stem cell nano-vesicle with a synergistic repairing effect, the stem cell nano-vesicle is prepared by sequentially and continuously performing hypoxia treatment, apoptosis induction and programmed series extrusion on stem cells, the average particle size of the stem cell nano-vesicle is 100-300nm, the polydispersity index is 0.05-0.30, the average particle size is 100-300nm, the average particle size is 100-300nm, the average particle size is 1-10nm, the average particle size is 1-10nm, and the stem cell nano-vesicle has a synergistic repairing effect. The expression rate of phosphatidylserine on the surface of the vesicle is greater than 40%. The stem cell nano-vesicle can promote endothelial cell migration and angiogenesis and maturation, can induce M1 type proinflammatory macrophages to be polarized into M2 type anti-inflammatory macrophages, and can release and repair cell factors in a large quantity. Compared with exosomes and other known nano-vesicles, the stem cell nano-vesicle disclosed by the invention has stronger functions of promoting angiogenesis, regulating immunity and repairing.

The invention discloses application of a (+)-JQ1 and Pracinostat pharmaceutical composition in preparation of a medicine for treating cervical cancer, and belongs to the technical field of biological medicines. The pharmaceutical composition comprises a BET inhibitor (+)-JQ1 and an HDAC inhibitor Pracinostat in effective treatment dose, a cervical cancer cell model is utilized, the anti-cervical cancer cell effect of the (+)-JQ1 combined with the Pracinostat is evaluated on the cellular level, the result shows that the synergistic index of the (+)-JQ1 combined with the Pracinostat for killing tumor cells is 15.079, the pharmaceutical composition has remarkable synergistic proliferation inhibition and apoptosis induction effects, and the pharmaceutical composition is suitable for clinical application. The effect is far better than that of single-drug treatment. The (+)-JQ1 and Pracinostat combination provided by the invention shows the activity of cooperatively killing cervical cancer cells, and has a wide prospect of being developed into drugs for treating cervical cancer.

The application discloses a compound drug-loaded exosome for overcoming cancer TRAIL drug resistance and a preparation method thereof, relates to the technical field of compound nano-drug preparation, and comprises an engineered exosome and an interfering RNA targeting a natriuretic peptide receptor A gene, wherein the engineered exosome is derived from a cell capable of expressing a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and carries the TRAIL protein; the interfering RNA is loaded in the engineered exosome; and the engineered exosome and the interfering RNA synergistically act to silence the NPRA gene through the interfering RNA to overcome the drug resistance of cancer cells to TRAIL. The application can silence the NPRA gene and remodel the apoptosis sensitivity of tumor cells through multiple channels, thereby efficiently overcoming the TRAIL drug resistance.

The invention discloses a traditional Chinese medicine composition for treating tumor cancer and a preparation method thereof. The traditional Chinese medicine composition is prepared from 20 traditional Chinese medicinal materials including curcuma zedoary, rhizoma sparganii, radix clematidis and the like through a special processing technology. The anti-tumor effect is achieved through triple mechanisms of cell apoptosis induction, angiogenesis inhibition and immunoregulation. The data of the embodiment shows that the IC50 value of the composition to the liver cancer HepG2 cell strain is 8.7 mu g / mL, and the tumor inhibition rate of tumor-bearing mice reaches 63.2%, which is obviously superior to that of a cis-platinum control group. The invention also provides a preferable alcohol extraction-water precipitation combined preparation process.

The present invention relates to a method for producing a modified mRNA construct in which a nucleotide derivative is coupled to the 3' terminus of mRNA by non-enzymatic extension using a nucleotide activated with imidazole or 2-aminoimidazole or a derivative thereof, and to enhancement of antigen protein translation efficiency resulting therefrom. When the modified mRNA construct of the present invention is applied to expression of an anticancer gene, an apoptosis-inducing effect in cancer cells can increase, and an anticancer effect in which EZH2 expression is reduced can be exhibited.

This invention discloses an acidic polysaccharide from Gynostemma pentaphyllum, AGPA12, its purification and extraction method, and its application in the preparation of anti-pancreatic cancer drugs. AGPA12 is mainly composed of mannose, glucuronic acid, rhamnose, glucose, galactose, and fucose, with a molar ratio of 1.05:1.74:6.29:1.40:69.48:19.03. The polysaccharide was extracted using an α-amylase-assisted water extraction and alcohol precipitation method, and purified by DEAE-Sepharose FF ion exchange chromatography and Sepharose CL6B gel chromatography. In vitro experiments showed that AGPA12 had significant inhibitory effects on the proliferation and migration of human pancreatic cancer AsPC1 cells, and its mechanism was related to the regulation of the MAPK signaling pathway and the expression of apoptosis-related proteins. This invention provides a new approach for the development of Gynostemma pentaphyllum polysaccharides and their application in anti-pancreatic cancer drugs.

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a platinum (IV) prodrug with ferroptosis and apoptosis induction effects as well as a preparation method and application of the platinum (IV) prodrug. According to the invention, a novel platinum (IV) compound with a ferroptosis induction effect is developed based on platinum (IV) prodrugs of salazosulfapyridine, cis-platinum and carboplatin; the platinum (IV) prodrug disclosed by the invention shows excellent anti-proliferative activity to cisplatin-sensitive and drug-resistant triple negative breast cancer cells, and compared with cisplatin, the platinum (IV) prodrug has lower activity to a normal mammary gland cell line (MCF-10A). Accumulation of reactive oxygen species (ROS) in cells can be improved by inducing DNA damage, and a mitochondrial dependent approach is activated to induce apoptosis. Meanwhile, accumulation of lipid peroxide can be remarkably promoted, xCT and GPX4 levels are reduced, and mitochondrial morphological change is induced to stimulate ferroptosis; in vivo, the cis-platinum (IV) prodrug shows strong anti-tumor activity in an MDA-MB-231 / CDDP xenograft model, and the cis-platinum (IV) prodrug has strong anti-tumor activity; the platinum (IV) prodrug has a potential application prospect in targeted therapy of triple negative breast cancer.

This invention relates to miRNAs and their uses in diagnosis and treatment, specifically providing the use of agents such as miR-494-3p or variants thereof, or analogs thereof, in the preparation of pharmaceutical compositions for the prevention or treatment of diseases induced by necrosis and apoptosis. This invention demonstrates that miRNAs directly participate in the occurrence of diseases induced by necrosis and apoptosis and can be used for the treatment of these diseases.

The invention belongs to the field of biomedical engineering, and particularly relates to a preparation method and application of a stem cell membrane bionic nano system. The invention provides a preparation method and application of a stem cell membrane bionic nano system. The system is endowed with excellent blood-brain barrier penetrating power and tumor active homing targeting property through stem cell membrane wrapping; by using the triphenylphosphine modified carbon dots, accurate mitochondrial targeting can be realized in the stem cell membrane bionic nano system, and apoptosis induction is enhanced; the stem cell membrane bionic nano system can realize integration of photo-thermal therapy, photodynamic therapy, nano-enzyme catalytic therapy and mitochondrial targeted therapy, multi-dimensionally kill tumor cells and destroy the steady state of a tumor microenvironment. The invention has a good application prospect in preparation of medicines for preventing or treating tumors.

The application discloses a photosensitive iridium complex with mitochondrial targeting and apoptosis induction and a preparation method thereof, and more particularly discloses a 2,2'-bipyridine compound, a cyclometalated iridium complex comprising the compound as a ligand, a preparation method and application as an antitumor drug. The cyclometalated iridium complex provided by the application takes the 2,2'-bipyridine compound as a ligand, can selectively induce tumor cell apoptosis under light conditions, can be used for preparing an antitumor drug and has great potential value in the field of photodynamic treatment of tumors.